Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis

13 Jan 2020

Abstract excerpt

Abstract Farnesoid X receptor (FXR) is a promising target for nonalcoholic steatohepatitis (NASH) and fibrosis. Although various FXR agonists have shown anti-fibrotic effects in diverse preclinical animal models, the response rate and efficacies in clinical trials were not optimum. Here we report that prophylactic but not therapeutic administration of obeticholic acid (OCA) prevents hepatic stellate cell (HSC)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Transport and Resistance Mechanisms
Share to Liver Disease Diagnosis and Treatment
Share to Liver physiology and pathology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31932588
DOI: 10.1038/s41467-019-14138-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosisPMID 31932588Read ↗

Notoginsenoside R1 targets PPAR-γ to inhibit Hepatic Stellate Cell activation and ameliorates liver fibrosisSemantic proximity Read ↗

The Role of Nuclear Receptors in the Pathogenesis and Treatment of Non-alcoholic Fatty Liver DiseaseSemantic proximity Read ↗

A CK2-RNF4 interplay coordinates non-canonical SUMOylation and degradation of nuclear receptor FXR.Semantic proximity Read ↗

Structural Basis of Novel Bile Acid-Based Modulators of FXRSemantic proximity Read ↗

Unlocking therapeutic potential: exploring cross-talk among emerging nuclear receptors to combat metabolic dysfunction in steatotic liver diseaseSemantic proximity Read ↗

Targeting EIF5A improves liver fibrosis by inhibiting mitochondrial function of hepatic stellate cellsSemantic proximity Read ↗

SUMO : A new perspective to decipher fibrosisSemantic proximity Read ↗

Ginkgolic acid attenuates <i>echinococcus granulosus</i> infection-induced hepatic fibrosis by inhibiting Smad4 SUMOylationSemantic proximity Read ↗

Inhibition of histone methyltransferase G9a aggravates phenotypic severity of hepatic lipotoxicity in non-alcoholic steatohepatitis (NASH).Semantic proximity Read ↗

GTX-11 improves portal hypertension, liver fibrosis, and sinusoidal cells phenotype in experimental MASHSemantic proximity Read ↗

Discovery biomarker to optimize obeticholic acid treatment for non-alcoholic fatty liver diseaseSemantic proximity Read ↗

Alleviation of liver fibrosis by inhibiting a non-canonical ATF4-regulated enhancer program in hepatic stellate cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.